StockpollyBeta
Get App
NUVL · NASDAQ · Biotechnology

Nuvalent (NUVL)

Developer of selective kinase inhibitors targeting ROS1 and ALK resistance in lung cancer.

$123.96
0.00 (0.00%)
Delisted · Jul 16, 2026

In millions of USD, except per-share figures

In millionsQ2 FY23Jun 2023Q3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026
3439465365768695105113102119
Research & development263036394961697481846884
8911141616172024293436
General & administrative8911141616172024293436
Operating income−34−39−46−53−65−76−86−95−105−113−102−119
55888−812105−10−1610
Interest income55888913121110210
Interest expense0000000000013
Other non-operating income00−8−8−88−12−10−51016−23
Income before tax−29−34−38−44−57−84−75−84−100−122−119−109
Income tax expense000000000000
Net income from continuing operations−29−34−38−44−57−84−75−85−100−122−119−109
Net income−29−34−38−44−57−84−75−85−100−122−119−109
EPS, basic−$0.51−$0.59−$0.62−$0.69−$0.88−$1.28−$1.05−$1.18−$1.39−$1.70−$1.58−$1.39
EPS, diluted−$0.51−$0.59−$0.62−$0.69−$0.88−$1.28−$1.05−$1.18−$1.39−$1.70−$1.58−$1.39
Weighted average shares, basic575762646566717272727579
Weighted average shares, diluted575762646566717272727579
EBITDA−34−39−36−44−57−84−75−84−100−122−16−96
Depreciation & amortization00300000001020
EBIT−34−39−38−44−57−84−75−84−100−122−119−96